CAL-130

产品编号 T10660Cas号 1431697-74-3

别名

CAL-130 is a PI3Kδ and PI3Kγ inhibitor (IC50s: 1.3 and 6.1 nM).

产品编号 T10660Cas号 1431697-74-3

CAL-130 is a PI3Kδ and PI3Kγ inhibitor (IC50s: 1.3 and 6.1 nM).

大包装 & 定制

加入购物车

实验操作小课堂

联系我们获取更多批次信息

资源下载

TargetMol 的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

生物活性

产品描述	CAL-130 is a PI3Kδ and PI3Kγ inhibitor (IC50s: 1.3 and 6.1 nM).
靶点活性	p110β:56 nM, p110δ:1.3 nM, p110α:115 nM, p110γ:6.1 nM
体外活性	CAL-130 preferentially inhibits the function of both p110γ and p110δ catalytic domains (IC50s: 1.3 and 6.1 nM for p110δ and p110γ, 115 and 56 nM for p110α and p110β). CAL-130 does not inhibit additional intracellular signaling pathways (i.e., p38 MAPK or insulin receptor tyrosine kinase) that are critical for general cell function and survival.
体内活性	The clinical significance of interfering with the combined activities of PI3Kγ and PI3Kδ is determined by administering CAL-130 to Lck/Ptenfl/fl mice with established T cell acute lymphoblastic leukemia. Candidate animals for survival studies are ill-appearing, have a white blood cell count above 45,000/μL, evidence of blasts on peripheral smear, and a majority of circulation cells (>75%) staining double-positive for Thy1.2 and Ki-67. Mice receive an oral dose (10 mg/kg) of CAL-130 every 8 hr for a period of 7 days and are then followed until moribund. Despite the limited duration of therapy, CAL-130 is highly effective in extending the median survival for treated animals to 45 days as compared to 7.5 days for the control group.